Envisioning the Future of Ocular Therapeutics
About Us | Unmet Needs | Technologies | Product Pipeline | Media & Investors


This menu lists current news relating to corporate activities and resources or internet links relating to our industry.

Phase 1/2 Uveitis Clinical Trial Evaluating DSP-Visulex-TM Now Open for Enrollment - 12/02/2014

The NEI Awards $2.03 Million Commercialization SBIR Grant to Aciont - 05/09/2013
Salt Lake City, UT – May 9, 2013. The National Eye Institute (NEI), a division of the National Institutes of Health (NIH), awarded a $2.03 million phase IIB grant to Aciont Inc. to fund the clinical development of a non-invasive, passive diffusion-based treatment for uveitis (referred to as DSP-Visulex-TM). The NEI special emphasis peer review panel that reviewed Aciont’s proposal stated, “Overall, this is a novel, exciting approach that has potential to make a broad impact in the clinical ophthalmology field and thus is recommended with a high level of enthusiasm.”
NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont® - 12/10/2009
The National Eye Institute (NEI) awarded a $2.18 million grant to Aciont Inc. to help fund its development of a non-invasive, passive diffusion-based treatment for severe, non-infectious uveitis.
Tribute to William I. Higuchi in Journal of Pharmaceutical Sciences - 01/15/2008
Dr. Higuchi's contributions have significantly elevated the field of pharmaceutics. He has an impressive body of scientific work and a continuing legacy of his accomplishments.
DSP-Visulex Studies in the Treatment of a Pan Uveitis Model Published in the Journal of Ocular Pharmacology and Therapeutics - 11/07/2017
DSP-Visulex technology study was published in the November issue of the Journal of Ocular Pharmacology and Therapeutics, volume 33, number 9, under the title “Noninvasive Ocular Drug Delivery System of Dexamethasone Sodium Phosphate in the Treatment of Experimental Uveitis Rabbit.”
Aciont To Present Phase 1/2 Clinical Trial Top Line Data at The 9th Annual Ophthalmology Innovation Summit at AAO - 11/08/2017
John Higuchi, Aciont's CEO, will be presenting topline data of Aciont’s lead product, DSP-Visulex in a phase 1/2 clinical trial in the treatment of noninfectious, anterior uveitis (DSPV-201).